Medulläres Schilddrüsenkarzinom

Benker G, Reinwein D (1983) Ergebnisse der Chemotherapie des Schilddrüsenkarzinoms. Dtsch Med Wochenschr 108: 403–406PubMedCrossRefGoogle Scholar

Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C (1993) Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Cancer 72: 3685–3693PubMedCrossRefGoogle Scholar

Calmettes C, Ponder BAJ, Fischer JA, Raue F (1992) Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. Eur J Clin Invest 22: 755–760PubMedCrossRefGoogle Scholar

Dralle H, Scheuermann GFW, Kotzerke J, Brabant EG (1992) Surgical management of MEN 2. Recent Results Cancer Res 125: 167–195PubMedCrossRefGoogle Scholar

Dralle H, Damm I, Scheumann GFW, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Jpn J Surg 24: 112–121Google Scholar

Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C (1990) Chemotherapy in metastatic nonanaplastic thyroid cancer. Experience at the Institut Gustave-Roussy. Tumori 76: 480–483PubMedGoogle Scholar

Frank-Raue K, Raue F, Ziegler R (1995) Therapie des metastasierten medullären Schilddrüsenkarzinoms mit dem Somatostatinanalogon Octreotide. Med Klin 90: 63–66Google Scholar

Grauer A, Raue F, Gagel RF (1990) Changing concepts in the management of hereditiary and sporadic medullary thyroid carcinoma. Endocr Metab Clin North Am 19: 613–535Google Scholar

Hedinger C, Williams ED, Sobin LH (1988) Histological typing of thyroid tumours. Springer, Berlin Heidelberg New York Tokyo, pp 11–13CrossRefGoogle Scholar

Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Hanley D, Goldenberg DM (1995) Targeting and treatment of medullary thyroid cancer (MTC) with radiolabelled monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA). Proc Am Soc Clin Oncol 14 [Abstract]: 1342Google Scholar

Raue F (ed) (1992) Medullary thyroid carcinoma. Recent results in cancer research, vol 125. Springer, Berlin Heidelberg New York Tokyo, pp 1–216Google Scholar

Raue F, Kotzerke J, Reinwein JD et al. (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the german medullary thyroid carcinoma register. Clin Invest 71: 7–12CrossRefGoogle Scholar

Raue F, Scherübl H (1993) Medikamentöse Therapie des Schilddrüsenkarzinoms. Med Welt 44: 692–696Google Scholar

Samonigg H, Hossfeld DK, Spehn J, Fill H, Leb G (1988) Aclarubicin in advanced thyroid cancer: a phase II study. Eur J Cancer Clin Oncol 24: 1271–1275PubMedCrossRefGoogle Scholar

Scherübl H, Raue F, Ziegler R (1990) Kombinationstherapie von Adriamycin, Cisplatin und Vindesin beim C-Zell-Karzinom der Schilddrüse. Onkologie 13: 198–202PubMedCrossRefGoogle Scholar

Shimaoka K, Schoenfeld DA, Dewys WD, Creech RH, Deconti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155–2160PubMedCrossRefGoogle Scholar

Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a southeastern cancer study group trial. Cancer Treat Rep 70: 405–407PubMedGoogle Scholar

Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73 (2): 432–436PubMedCrossRefGoogle Scholar